47 results about "Photoreceptor cell" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

The present disclosure provides short enhanced human opsin promoters for rod-specific expression that satisfy a need in the art for promoters that are able to control transgene expression both efficiently and selectively in rod cells, with little to no off-target expression in other photoreceptor cells. The disclosure provides vector constructs comprising transgenes operably controlled by this enhanced human opsin promoter that may be delivered and targeted with high specificity to rod cells. The disclosure also provides compositions comprising these vector constructs and methods for administration of these compositions to subjects in need thereof.

Injectable photoelectrohydrogel for repairing retinal photoreceptor damage and its preparation method and application, photoelectroactive spirulina and conductive polymer poly(3,4-ethylenedioxythiophene) (PEDOT) hydrogel are physically cross-linked to construct an injectable material with photoelectric response characteristics, and the function of damaged photoreceptor cells in the retina is repaired in situ. Sp as a biologically active component not only gives the material photoelectric signal conversion capability, but also can achieve local antioxidant stress function, PEDOT-based hydrogel forms a three-dimensional scaffold by physically wrapping Sp, which not only ensures the activity of algal cells but also has excellent charge and ion conduction performance. The hydrogel can be injected into the retina to construct a biomimetic electrochemical signal transmission interface, rebuild the signal transduction of damaged photoreceptor cells, and realize the in situ repair of retinal signal pathways and the partial recovery of visual function. This technology provides a new strategy for the curative treatment of retinal diseases such as blinding eye diseases, and has the advantages of minimally invasive intervention, excellent biocompatibility and customizable treatment area.

The disclosure relates to methods of treating photoreceptor disease and / or inhibiting degeneration or death of photoreceptors. The methods comprise administering to a subject in need thereof a therapeutically effective amount of an inhibitor of mitogen-activated protein kinase 11 (MAPK11), an inhibitor of casein kinase 1 (CK1), or combinations thereof. This disclosure also relates to certain inhibitors of MAPK11 or CK1 and to pharmaceutical compositions that contain such inhibitors.

The utility model relates to a kind of delay myopia degree progress and axial growth prevention and control spectacle lens, belong to the field of glasses optics.The lens includes lens base, and the center area is circular center visible area, and outside is peripheral defocus area.Peripheral defocus area is composed of microlens array, and is divided into two asymmetric design regions from central axis: upper half adopts circular ring array structure, and lower half adopts concentric honeycomb array structure.Effective inhibition vision deepens, improve myopia management effect.Peripheral defocus area defocus gradually reduces from center to outside, more fit 8-18 years old teenager eyeball retina structure features.Microlens gap place evenly densely multiple diffusion points, effectively reduce contrast, brightness by soft scattered light, reduce hue difference;Reduce the high contrast signal detected by retina photoreceptor cell and its elongation signal to eye, so as to delay axial growth, delay myopia deepens.

This invention discloses the application of the VDAC2 gene or VDAC2 protein as a target in screening drugs for the treatment of retinitis pigmentosa, relating to the field of biomedical technology. The drug is one that reduces the expression level of the VDAC2 gene or inhibits the expression level or activity of the VDAC2 protein; the CDS sequence of the VDAC2 gene is shown in SEQ ID NO.1. This invention uses a rod cell-specific promoter to inhibit VDAC2 expression, which can significantly improve the survival rate of local photoreceptor cells. This method intervenes in the early stages of the disease, conforming to the natural course of RP. It strengthens the function of rod cells before a large number of photoreceptor cells die, delaying their degenerative process and indirectly protecting cone cells, thereby prolonging the patient's effective visual retention time. This overcomes the shortcomings of existing gene therapies, which are mainly applicable to late-stage or specific mutation types, and provides a therapeutic basis for retinitis pigmentosa.

The present disclosure relates to compositions, methods and related uses for preventing, inhibiting, ameliorating or delaying (slowing): (i) the thinning of the retinal outer nuclear layer (ONL), and / or (ii) reduction in total retinal thickness in a subject. The present disclosure further relates generally to compositions, methods and related uses for protecting: (i) the retinal outer nuclear layer (ONL) and / or the retina from light- or age-induced damage, and / or (ii) photoreceptors from light- or age-induced damage. In particular, the present technology relates to administering bevemipretide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof to subjects in need thereof.

This approach provides an opportunity to inhibit photoreceptor degeneration by knocking out the SARM1 gene, thereby sustaining photoreceptors in the eye. [Solution] A method is provided for inactivating alleles of the steryl alpha and toll / interleukin-1 receptor motif-containing 1 (SARM1) gene in cells, comprising introducing into the cells a composition comprising at least one CRISPR nuclease, or a sequence encoding a CRISPR nuclease; and an RNA molecule comprising a guide sequence portion, wherein the complex of the CRISPR nuclease and the RNA molecule acts to break the double strand in the allele of the SARM1 gene, and the guide sequence portion of the RNA molecule comprises 17 to 50 consecutive nucleotides.

The invention discloses application of Hinderein protein in regulation and control of cilia length and the fields of biomedicine and molecular cell biology, in-vivo and in-vitro experiments prove that knockdown or knockout of Hinderein can cause significant shortening of cilia length of mouse retina photoreceptor cells and APRE19 cells, but does not affect the occurrence rate of cilia, and mechanism research shows that knockdown or knockout of Hinderein can cause significant shortening of cilia length of mouse retina photoreceptor cells and APRE19 cells without affecting the occurrence rate of cilia. The Hinderein interacts with the central grain satellite protein PCM1, and is crucial to the positioning of the Hinderein around the central grain. Therefore, the Hinderein protein, the agonist of the Hinderein protein or the coding gene of the Hinderein protein can be used for preparing products for promoting cilia elongation, and a new target spot is provided for treatment of diseases related to abnormal cilia length.

This suppresses image defects caused by toner being reverse-transferred to the photoreceptor. [Solution] The image forming apparatus comprises a photoreceptor, a charging member, a developing unit, a transfer unit, a recovery member disposed downstream of the transfer unit and upstream of the charging member, which electrostatically recovers the reverse transfer toner having a first color transferred from the transfer member to the surface of the photoreceptor by the transfer unit, and a control unit that controls the voltage applied to the charging member and the recovery member, respectively. When the absolute value of the potential of the recovery member during image formation is V1 and the absolute value of the surface potential of the photoreceptor before passing through the recovery member is V2, the control unit controls V2

A method of treating a cone photoreceptor cell-associated disorder in a subject in need of such therapy by administering to the eye of the subject a recombinant vector comprising: (a) a coding sequence encoding a synoviolin 1 (SYVN1) protein, and (b) a promoter region, wherein the promoter region is specific for cone photoreceptor cells, wherein the coding sequence is operatively linked to the promoter region, and wherein in vivo expression of the SYVN1 protein in the cone photoreceptor cells of the subject serves to treat the cone photoreceptor cell-associated disorder in the subject.

Methods are provided for treating and diagnosing diseases and disorders associated with retinal degeneration, such as retinitis pigmentosa. Dietary supplementation with specific metabolites and vitamins can prolong vision and provide a neuroprotective effect. In particular, dietary supplementation with a-ketoglutarate, or a derivative thereof, significantly prolongs photoreceptor cell survival and visual function. In addition, dietary supplementation with B vitamins and a ketogenic diet also improves photoreceptor cell survival and delays disease progression in some cases. Additionally, compositions, methods, and kits are provided for diagnosing a subject with retinitis pigmentosa based on expression levels of vitreous biomarkers.

As a technique useful in genome editing of a rhodopsin (RHO) locus using a zinc finger nuclease (ZFN), a combination of one pair of ZFNs, which is a combination of ZFNs having a zinc finger array that recognizes a specific nucleic acid sequence, for genome editing of the RHO locus is provided.

The present invention relates to retinal progenitor cells simultaneously exhibiting characteristics of retinal pigment epithelial cells, photoreceptor cells, and lens epithelial cells, and a mass production method therefor. When retinal progenitor cells are isolated and cultured using the method according to one aspect, the retinal progenitor cells can be mass-produced in a short time, and thus the method is economical. In addition, the isolated retinal progenitor cells exhibit all of the differentiation characteristics of retinal pigment epithelial cells, photoreceptor cells and lens epithelial cells. Therefore, the present invention can be effectively used in the fields of research on retinal diseases such as macular degeneration, and research and development of therapeutic agents.

Provided are a photoreceptor cell-specific bidirectional promoter and the use thereof. Specifically, the present invention relates to a new photoreceptor cell-specific bidirectional promoter, an expression cassette, vector, virus particle, cell and pharmaceutical composition containing the bidirectional promoter, and the use thereof in the treatment of ocular diseases such as retinal diseases.

The present disclosure relates to compositions, methods and related uses for preventing, inhibiting, ameliorating or delaying (slowing): (i) the thinning of the retinal outer nuclear layer (ONL), and / or (ii) reduction in total retinal thickness in a subject. The present disclosure further relates generally to compositions, methods and related uses for protecting: (i) the retinal outer nuclear layer (ONL) and / or the retina from light- or age-induced damage, and / or (ii) photoreceptors from light- or age-induced damage. In particular, the present technology relates to administering bevemipretide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof to subjects in need thereof.

This invention discloses the application of disodium 4,4'-diisothiocyanate-2,2'-stilbene sulfonate in the preparation of drugs for the prevention, delay, and / or treatment of blue light-induced retinal damage. It belongs to the field of biomedical technology. This invention demonstrates for the first time that sodium DIDS can effectively protect photoreceptor cells from blue light damage: at the cellular level, sodium DIDS can restore mitochondrial membrane potential, increase ATP levels, reduce reactive oxygen species accumulation, and inhibit mitochondrial-dependent apoptosis; at the animal level, intravitreal injection of sodium DIDS can improve vision in mice exposed to blue light, restore the amplitude of a-waves and / or b-waves in electroretinograms, and protect the outer segment length and outer nuclear layer thickness of cone cells. Sodium DIDS provides a novel therapeutic strategy for blue light-induced retinal photodamage through multi-target synergistic protection of mitochondrial function.

A blade (1) for a wind power generator has a surface covered with a reflective material layer (12) made of a light-reflecting material that reflects light such that, when light is incident on a compound eye of an insect, at least three types of photoreceptor cells present in the ommatidium constituting the compound eye contain visual pigments having different absorption wavelength bands, which are the wavelength bands of light to be absorbed, and the difference in light intensity in the absorption wavelength bands of the visual pigments contained respectively in multiple types of photoreceptor cells constituting a part of the ommatidium of the compound eye of the insect that are excited upon absorption of light is equal to or less than a predetermined intensity difference threshold.

The invention discloses application of salvianolic acid C in preparation of a medicine for preventing and / or treating retinal ischemia hypoxic nerve injury diseases, and relates to the technical field of biological medicines. The invention proposes and verifies for the first time that salvianolic acid C can significantly promote the formation of stress particles in photoreceptor cells under retinal ischemia and hypoxia conditions, and drives the salvianolic acid C to be assembled into a stress particle-mitochondrial micro-region in a mitochondrial adjacent region. The microcell is enriched in DDX3X, LARP1 and other key RNA binding proteins and multiple mitochondrial related proteins to cooperatively maintain mitochondrial membrane potential, inhibit mPTP opening and reduce ROS generation, so that an endogenous apoptosis pathway is inhibited, and the neuroprotective effect on a photoreceptor is achieved. On the basis, the salvianolic acid C is used for preparing the medicine for preventing and / or treating the retinal ischemia hypoxia nerve injury disease, can be used as a nerve protection supplement for existing anti-VEGF treatment, and has innovativeness and application value.

Provided herein are genetically engineered promoter-enhancer constructs for altering transcription of a gene operably linked thereto having specificity for expression in photoreceptor cells. Also provided are methods of use for these photoreceptor-specific promoter-enhancer genetic constructs; a pharmaceutical composition comprising these constructs, and methods of using the pharmaceutical composition for treating retinal diseases.

The blade (1) for a wind power generator has a surface covered with a reflective material layer (12) made of a light-reflecting material that reflects light such that when light is incident on an insect's compound eye, at least three types of photoreceptors present in the ommatidium that make up the compound eye contain visual pigments with different absorption wavelength bands, which are the wavelength bands of light that the photoreceptors absorb, and the difference in light intensity in the absorption wavelength bands of the visual pigments contained in each of the multiple types of photoreceptors that make up part of the ommatidium of the insect's compound eye become excited when they absorb light, is equal to or less than a predetermined intensity difference threshold.

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

The present invention provides a method of making a cone degeneration model comprising the step of activating specific cell death in at least one cone photoreceptor cell. Also provided are methods for isolating compounds capable of protecting cone photoreceptor cells from denaturation.

rAAV particles comprising a new capsid variant, AAV44.9(E531D) are described herein, as well as a polynucleotide encoding same, and the use of the rAAV particles in the treatment of the eye, including treatment of retinal disorders. The disclosure also shows that the rAAV particles comprising an AAV44.9(E531D) capsid exhibit enhanced lateral spread after subretinal injection to a fovea of the subject, wherein detachment of the fovea is minimized. Methods of treatment comprising administering rAAV particles to a mammal in need thereof, and methods of transducing photoreceptor and RPE cells with rAAV particles, are also provided.

The invention relates to the field of application of natural products, in particular to application of a Chinese wolfberry extract in prevention and / or treatment of age-related retinopathy. The fructus lycii extract can increase the number of photoreceptor cells in age-related retina, improve the signal transmission capacity of an inner nuclear layer of the retina, increase the total thickness of the age-related retina and increase the thickness of an outer nuclear layer of the age-related retina.

The disclosure relates to methods of treating photoreceptor disease and / or inhibiting degeneration or death of photoreceptors. The methods comprise administering to a subject in need thereof a therapeutically effective amount of an inhibitor of mitogen-activated protein kinase 11 (MAPK11), an inhibitor of casein kinase 1 (CK1), or combinations thereof. This disclosure also relates to certain inhibitors of MAPK11 or CK1 and to pharmaceutical compositions that contain such inhibitors.

Develop the photoreceptor unit. [Solution] A photoreceptor unit that can be attached to the main body of an image forming apparatus having a first main body side bevel gear section and a second main body side bevel gear section that rotate coaxially, comprising: a photoreceptor rotatable about a rotation axis; a first unit side bevel gear section for meshing with the first main body side bevel gear section; and a second unit side bevel gear section for meshing with the second main body side bevel gear section, wherein the twist direction of the teeth of the second unit side bevel gear section is the same as the twist direction of the teeth of the first unit side bevel gear section, and the twist angle of the teeth of the second unit side bevel gear section is greater than the twist angle of the teeth of the first unit side bevel gear section, and the first unit side bevel gear section and the second unit side bevel gear section rotate while the first unit side bevel gear section meshes with the first main body side bevel gear section and the second unit side bevel gear section meshes with the second main body side bevel gear section.

Provided herein are methods of enriching for photoreceptors and photoreceptor precursor cells from mixed cell populations. Such enriched populations of photoreceptors and photoreceptor precursor cells can be used as cell therapies for the treatment of retinal disorders.

The invention discloses a ferritin-coupled melanin nano-particle and a preparation method and application thereof, and relates to the technical field of biomedicine, the ferritin-coupled melanin nano-particle AFn-MNP comprises ferritin and a melanin nano-particle, the ferritin and the melanin nano-particle are covalently linked to form a core-shell structure, and the ferritin-coupled melanin nano-particle has excellent iron ion chelating ability and antioxidant activity. The AFn-MNP can effectively remove reactive oxygen species (ROS), inhibit ferroptosis of photoreceptor cells and reverse oxidative damage of retina. In a dry age-related macular degeneration (dAMD) model, single intravitreal injection of AFn-MNP significantly improves the visual function and protects the retina structural integrity. The invention provides a novel nano treatment strategy for treating dAMD and other retinal degenerative diseases.

The invention relates to the technical field of biology, in particular to application of beta-hydroxybutyrylation modification in preparation of a medicine for treating diabetic retinopathy. According to the application, the inducer for promoting beta-hydroxybutyrylation modification is used for preparing the medicine for preventing and / or treating diabetic retinopathy. The application is based on an in-vitro experiment, and proves that after beta-hydroxybutyrate intervention, beta-hydroxybutyrate is modified by beta-hydroxybutyrylation, so that apoptosis of a mouse retinal ganglion cell strain induced by an advanced glycosylation end product can be reduced; western blot proves that beta-hydroxy butyrylation modification of cells in a ganglion cell layer and a photoreceptor cell layer is induced in the retina in a diabetic animal body after beta-hydroxybutyrate intervention, which shows that the diabetic retina can be prevented and treated by inducing and promoting beta-hydroxy butyrylation modification; the blank between the beta-hydroxyl butyrylation modification and the diabetic retinopathy in the existing research is filled.